$SXTP News

60 Degrees Pharmaceuticals Enters Exclusive Option Agreement With Florida State's Research Foundation Regarding IP To Develop Castanospermine For Multiple Tick-Borne Diseases

60 Degrees Pharma's B-Free Babesiosis Trial Clears Initial Safety Review, Advances After DSMB Recommendation

60 Degrees Pharma Executes Patent Licensing Agreement With Florida State University To Commence Large-Scale Production Techniques To Extract, Purify Castanospermine From Seeds Of Australian Chestnut For Non-Prescription Uses

60 Degrees Pharmaceuticals Says Co. May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028

Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $3.7

HC Wainwright & Co. Downgrades 60 Degrees to Neutral

60 Degrees Q1 EPS $(1.28) Misses $(0.76) Estimate, Sales $76.377K Miss $435.000K Estimate

60 Degrees Pharma Says ARAKODA For Malaria Prevention Is Now Available For Purchase On Runway Health Website For U.S. Travelers

Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $4.2

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

Infrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference

60 Degrees Pharmaceuticals shares are trading higher. The company reported its Q4 financial results.

60 Degrees Pharmaceuticals shares are trading higher. The company reported its Q4 financial results.

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Q4 EPS $(1.47) Misses $(1.12) Estimate, Sales $303.385K Miss $400.000K Estimate

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification With FDA For Australian Chestnut Extract; Inks Deal To License Florida State University's Ownership Rights To New Capsule Formulation Methods For Australian Chestnut Extract

What's Going On With 60 Degrees Pharmaceuticals On Friday?

60 Degrees Pharmaceuticals shares are trading higher after the company announced that three of three enrolled patients have been cured of babesiosis after completing the tafenoquine regimen in the company's trial of relapsing babesiosis in immunosuppressed patients.